Description: Learn about LYBALVI, including dosing, efficacy, and safety. Please see Important Safety Info and full Prescribing Info, including Boxed Warning and Med Guide.
Indications: LYBALVI ® is indicated for the treatment of adults with schizophrenia or bipolar I disorder for acute treatment of manic or mixed episodes as monotherapy and as an adjunct to lithium or valproate, or as a maintenance monotherapy treatment.
* Source: IQVIA Total Prescriptions (TRx) Data October 2021 – February 2023 .
Bipolar I Disorder: LYBALVI TRx grew 4000% (from 67 to 2747). Market leader TRx decreased 5% (from 403,533 to 382,746).